Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Partial Inhibition Of The Key Glycolytic Enzyme Pfkfb3 In Myeloid Cells Impacts Whole-Body Immune Cell And Liver Metabolism, But Not Atherogenesis.
Joost D. de Bruijn, Kim van Kuijk, Mitchell Bijnen, Marion J. Gijbels, Kristiaan Wouters, Peter Carmeliet, Judith C. Sluimer (2019). Partial Inhibition Of The Key Glycolytic Enzyme Pfkfb3 In Myeloid Cells Impacts Whole-Body Immune Cell And Liver Metabolism, But Not Atherogenesis.. , 287, DOI: https://doi.org/10.1016/j.atherosclerosis.2019.06.055.
Article58 days agoPartial myeloid inhibition of key glycolytic enzyme PFKFB3 increases hepatic steatosis and inflammation, but does not affect atherosclerosis
R. Tillie, Joost D. de Bruijn, Ross Dobie, Javier Perales-Patón, Kim van Kuijk, Marion J. Gijbels, Lieve Temmerman, Yanal Ghosheh, Gijs H. Goossens, Peter Carmeliet, Klaus Ley, Neil C. Henderson, Julio Sáez-Rodríguez, Kristiaan Wouters, Judith C. Sluimer (2023). Partial myeloid inhibition of key glycolytic enzyme PFKFB3 increases hepatic steatosis and inflammation, but does not affect atherosclerosis. , 379, DOI: https://doi.org/10.1016/j.atherosclerosis.2023.06.961.
Article58 days ago